Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026
SEC Filing
Read original at benzingaStocks · News reference
8-K filing — Aldeyra Therapeutics, Inc. (ALDX)
Filed: 2026-07-30 AccNo: 0001193125-26-326337 Size: 20 MB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 30, 2026, 9:07 PM
- Checked
- Jul 30, 2026, 9:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading